Published in Future Microbiol on June 01, 2010
Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis (2010) 1.67
Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One (2012) 1.65
Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res (2013) 1.17
Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest (2015) 1.04
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr (2012) 1.04
Improved synthesis of capuramycin and its analogues. Chemistry (2013) 0.85
Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat Commun (2016) 0.84
Analysis of intracellular expressed proteins of Mycobacterium tuberculosis clinical isolates. Proteome Sci (2012) 0.84
New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist (2015) 0.82
Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target. PLoS One (2014) 0.80
Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. J Antimicrob Chemother (2015) 0.78
Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones. Tuberc Res Treat (2012) 0.77
Combating Tuberculosis Infection: A Forbidding Challenge. Indian J Pharm Sci (2016) 0.75
Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. Sci Rep (2016) 0.75
Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials. Perspect Medicin Chem (2015) 0.75
Bedaquiline. Br J Clin Pharmacol (2015) 0.75
Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives. Eur J Med Chem (2016) 0.75
Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents. ACS Med Chem Lett (2013) 0.75
Crystal structure of 5-hy-droxy-methyl-2-meth-oxy-phenol. Acta Crystallogr E Crystallogr Commun (2015) 0.75
The pregnane X receptor in tuberculosis therapeutics. Expert Opin Drug Metab Toxicol (2015) 0.75
Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother (2017) 0.75
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
WHO's new Stop TB Strategy. Lancet (2006) 5.59
Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet (2007) 3.65
Antituberculosis drugs: ten years of research. Bioorg Med Chem (2007) 3.53
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2008) 2.92
Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci U S A (2005) 2.84
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol (2007) 2.83
Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec (2006) 2.74
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet (1999) 2.62
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother (2007) 2.50
The tuberculosis X factor. Lancet Infect Dis (2006) 2.47
Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A (2000) 2.46
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother (2003) 2.44
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother (2008) 2.33
Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem (2008) 2.07
Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther (2007) 2.06
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother (2006) 1.97
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother (2006) 1.81
Will tuberculosis become resistant to all antibiotics? Proc Biol Sci (2001) 1.79
New tuberculosis therapeutics: a growing pipeline. J Infect Dis (2007) 1.78
In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother (2007) 1.68
Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother (2008) 1.53
Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med (2007) 1.46
Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother (2006) 1.36
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med (2009) 1.35
New small-molecule synthetic antimycobacterials. Antimicrob Agents Chemother (2005) 1.23
Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. Chem Biol Drug Des (2006) 1.17
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother (2008) 1.13
Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) (2008) 1.13
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med (2008) 1.11
ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother (2009) 0.94
Progress of DOTS in global tuberculosis control. Lancet (2006) 0.89
Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med (2009) 0.88
[R207910 (TMC207): a new antibiotic for the treatment of tuberculosis]. Med Mal Infect (2009) 0.85
The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother (2009) 0.84
Unorthodox approach to the development of a new antituberculosis therapy. N Engl J Med (2009) 0.83
Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database. Lancet Infect Dis (2012) 2.78
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Emerging multidrug resistant Mycobacterium tuberculosis strains of the Beijing genotype circulating in Russia express a pattern of biological properties associated with enhanced virulence. Microbes Infect (2010) 1.58
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis (2011) 1.07
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother (2013) 1.03
Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother (2013) 0.96
Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr (2016) 0.86
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis. AAPS J (2016) 0.84
Recombinant antigen production for assays of intradermoreaction for diagnosis and surveillance of tuberculosis. J Biotechnol (2011) 0.80
Immune function in young children with previous pulmonary or miliary/meningeal tuberculosis and impact of BCG vaccination. Pediatrics (2007) 0.80
Reply to Seddon, Schaaf, and Hesseling. Clin Infect Dis (2012) 0.75